Medifast Inc. Files Q2 2024 10-Q Report
Ticker: MED · Form: 10-Q · Filed: Aug 5, 2024 · CIK: 910329
Sentiment: neutral
Topics: 10-Q, earnings, financials
TL;DR
**MEDI Q2 10-Q FILED: Detailed financials for the period ending June 30, 2024, are now public.**
AI Summary
Medifast Inc. reported its second quarter results for the period ending June 30, 2024. The company's financial performance for this quarter and the preceding six months is detailed in this 10-Q filing. Specific revenue, profit, and balance sheet figures are provided for the periods ending June 30, 2024, and June 30, 2023, as well as for the six months ended June 30, 2024, and June 30, 2023.
Why It Matters
This filing provides investors with the official financial performance data for Medifast Inc. during the second quarter of 2024, crucial for understanding the company's current health and future prospects.
Risk Assessment
Risk Level: medium — The filing contains detailed financial information which could reveal trends or issues impacting the company's stock price.
Key Numbers
- 20240630 — Period End Date (Second quarter of 2024)
- 20230630 — Prior Year Period End Date (Second quarter of 2023)
- 20240101 — Year-to-Date Start Date (First six months of 2024)
- 20230101 — Prior Year Year-to-Date Start Date (First six months of 2023)
Key Players & Entities
- MEDIFAST INC (company) — Filer
- 20240630 (date) — Period of Report
- 20240805 (date) — Filing Date
- 001-31573 (company) — SEC File Number
FAQ
What is the reporting period for this 10-Q filing?
The Conformed Period of Report is 20240630, indicating the filing covers the period ending June 30, 2024.
When was this 10-Q filing submitted to the SEC?
The filing was submitted on 20240805.
What is Medifast Inc.'s SEC file number?
Medifast Inc.'s SEC file number is 001-31573.
What is the company's fiscal year end?
The company's fiscal year ends on 1231.
What industry is Medifast Inc. classified under?
Medifast Inc. is classified under Standard Industrial Classification 2090: Miscellaneous Food Preparations & Kindred Products.
Filing Stats: 4,800 words · 19 min read · ~16 pages · Grade level 14 · Accepted 2024-08-05 16:50:48
Key Financial Figures
- $0.001 — ich registered Common Stock, par value $0.001 per share MED New York Stock Exchange
Filing Documents
- med-20240630.htm (10-Q) — 949KB
- med-20240630xexx311.htm (EX-31.1) — 10KB
- med-20240630xexx312.htm (EX-31.2) — 10KB
- med-20240630xexx321.htm (EX-32.1) — 7KB
- 0001628280-24-034791.txt ( ) — 4768KB
- med-20240630.xsd (EX-101.SCH) — 30KB
- med-20240630_cal.xml (EX-101.CAL) — 63KB
- med-20240630_def.xml (EX-101.DEF) — 122KB
- med-20240630_lab.xml (EX-101.LAB) — 394KB
- med-20240630_pre.xml (EX-101.PRE) — 266KB
- med-20240630_htm.xml (XML) — 633KB
– Financial Statements
Item 1 – Financial Statements Condensed Consolidated Statements of Operations (unaudited) for the Three and Six Months Ended June 30, 2024 and 2023 2 Condensed Consolidated Statements of Comprehensive Income (Loss) (unaudited) for the Three and Six Months Ended June 30, 2024 and 2023 3 Condensed Consolidated Balance Sheets (unaudited) as of June 30, 2024 and December 31, 2023 4 Condensed Consolidated Statements of Cash Flows (unaudited) for the Six Months Ended June 30, 2024 and 2023 5 Condensed Consolidated Statements of Changes in Stockholders' Equity (unaudited) for the Three and Six Months Ended June 30, 2024 and 2023 6 Notes to Condensed Consolidated Financial Statements (unaudited) 7
– Management's Discussion and Analysis of Financial Condition and Results of Operations
Item 2 – Management's Discussion and Analysis of Financial Condition and Results of Operations 15
– Quantitative and Qualitative Disclosures about Market Risk
Item 3 – Quantitative and Qualitative Disclosures about Market Risk 26
– Controls and Procedures
Item 4 – Controls and Procedures 26
– Other Information
Part II – Other Information
– Legal Proceedings
Item 1 – Legal Proceedings 28
– Risk Factors
Item 1A – Risk Factors 28
– Unregistered Sales of Equity Securities and Use of Proceeds
Item 2 – Unregistered Sales of Equity Securities and Use of Proceeds 28
– Exhibits
Item 6 – Exhibits 29 1 Table of Contents MEDIFAST, INC. AND SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED) (U.S. dollars in thousands, except per share amounts & dividend data) Three months ended June 30, Six months ended June 30, 2024 2023 2024 2023 Revenue $ 168,558 $ 296,188 $ 343,297 $ 645,170 Cost of sales 45,120 85,473 92,567 188,065 Gross profit 123,438 210,715 250,730 457,105 Selling, general, and administrative 131,314 172,009 250,666 364,887 Income (loss) from operations ( 7,876 ) 38,706 64 92,218 Other income (expense) Interest income 1,296 462 2,519 281 Other expense ( 4,070 ) ( 51 ) ( 1,647 ) ( 53 ) ( 2,774 ) 411 872 228 Income (loss) from operations before income taxes ( 10,650 ) 39,117 936 92,446 Provision (benefit) for income taxes ( 2,496 ) 8,837 773 22,198 Net income (loss) $ ( 8,154 ) $ 30,280 $ 163 $ 70,248 Earnings (loss) per share - basic $ ( 0.75 ) $ 2.78 $ 0.01 $ 6.46 Earnings (loss) per share - diluted $ ( 0.75 ) $ 2.77 $ 0.01 $ 6.43 Weighted average shares outstanding Basic 10,937 10,888 10,923 10,876 Diluted 10,937 10,917 10,967 10,923 Cash dividends declared per share $ — $ 1.65 $ — $ 3.30 The accompanying notes are an integral part of these condensed consolidated financial statements. 2 Table of Contents MEDIFAST, INC. AND SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) (UNAUDITED) (U.S. dollars in thousands) Three months ended June 30, Six months ended June 30, 2024 2023 2024 2023 Net income (loss) $ ( 8,154 ) $ 30,280 $ 163 $ 70,248 Other comprehensive income (loss), net of tax: Foreign currency translation 32 90 43 99 Unrealized losses on investment securities ( 28 ) — ( 265 ) — 4 90 ( 222 ) 99 Comprehensive income (loss) $ ( 8,150 ) $ 30,370 $ ( 59 ) $ 70,347 The accompanying notes are an integral part of these condensed consolidated financial statements. 3 Table of Contents MEDIFAST, INC. AND SUBSIDIARIES CON